NYU Langone’S Perlmutter Cancer Center
Combination extends OS in immunotherapy-resistant advanced non-small cell lung cancer
CHICAGO — A new combination therapy benefitted certain patients with immunotherapy-resistant advanced non-small cell lung cancer, according to randomized phase 2 study results presented at ASCO Annual Meeting.
First-line brentuximab vedotin regimen extends OS in advanced classical Hodgkin lymphoma
CHICAGO — The addition of brentuximab vedotin to frontline chemotherapy significantly extended OS among patients with advanced classical Hodgkin lymphoma, according to study results presented at ASCO Annual Meeting.
Multiple myeloma specialist named inaugural director of blood cancer center
Faith E. Davies, MD, has been appointed the inaugural director of Center for Blood Cancers at NYU Langone Health’s Perlmutter Cancer Center.
Perlmutter Cancer Center appoints director of gynecologic oncology
Leslie R. Boyd, MD, has been appointed director of the division of gynecologic oncology at Laura and Isaac Perlmutter Cancer Center at NYU Langone Health.
Enfortumab vedotin confers benefit ‘across the spectrum’ of advanced urothelial carcinoma
Results of two studies presented at Genitourinary Cancers Symposium showed treatment with enfortumab vedotin-ejfv benefited patients with locally advanced or metastatic urothelial carcinoma previously treated with a PD-1 or PD-L1 inhibitor.
Quality of life comparable between niraparib, placebo in advanced ovarian cancer
Patients with gynecologic cancers that responded to first-line platinum-based chemotherapy receiving niraparib did not show lower health-related quality of life compared with placebo, according to data presented at ESMO Virtual Congress 2020.
Mount Sinai appoints director of gastrointestinal oncology program
Deirdre J. Cohen, MD, MS, has been appointed director of the gastrointestinal oncology program at Mount Sinai Health System.